Institute of Stem Cell

What Institute of Stem Cell does

inStem (Institute for Stem Cell Science and Regenerative Medicine), now operating as BRIC-inStem, is an autonomous government research institute established in 2009 in Bengaluru, India, under the Department of Biotechnology (DBT), Government of India. It was India's first institute dedicated exclusively to stem cell science and regenerative medicine, and was restructured in 2025 under the Biotechnology Research and Innovation Council (BRIC). The institute conducts basic and translational research across cardiovascular development, chemical biology, barrier tissue homeostasis, neurodevelopmental disease modeling, and metabolic regulation of cell fate. Core technology platforms include human embryonic stem cell lines of Indian origin, 3D organoid systems (brain, retinal, corneal, cardiovascular), CRISPR-Cas9 gene editing, SWI/SNF chromatin remodeling studies, advanced confocal and cryo-electron microscopy, and dedicated facilities for mass spectrometry, mouse genome engineering, pluripotent stem cell banking, and a national cryo-EM facility.

The institute's outputs include established Indian-origin human embryonic stem cell lines, the commercial launch of KisanKavach anti-pesticide fabric technology, and a first-in-human lentiviral gene therapy trial for Hemophilia A. inStem operates as part of the Bangalore Life Science Cluster (BLiSC) alongside NCBS-TIFR, TIGS, and C-CAMP, sharing infrastructure and faculty collaboration.

inStem does not operate a commercial business model. Revenue is derived primarily from DBT government grants, supplemented by international research funding from the Gates Foundation, Wellcome Trust India Alliance, Chan Zuckerberg Initiative, BIRAC, and EMBO, along with technology licensing and industry collaboration agreements (e.g., Dr Reddy's Laboratories). Pricing is non-commercial; research access occurs through academic collaborations, PhD/postdoctoral programs, internships, and industry partnerships. The institute's "customers" in a stakeholder sense are the academic research community, PhD students and fellows, and industry partners, with translational outputs (spin-offs, patents, technology transfer) representing the primary commercial-adjacent channel.

Name

Institute of Stem Cell

Legal name

Institute for Stem Cell Science and Regenerative Medicine

Website

https://instem.res.in

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

inStem (BRIC-inStem) is India's first government-funded autonomous research institute dedicated to stem cell science and regenerative medicine, based in Bengaluru under the Department of Biotechnology, conducting basic and translational research, training PhD students, and licensing translational technologies.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Health Security, Pandemic Preparedness & Response (IHR, EID) (BPADAIAH)

Keywords

• Stem cell research
• Regenerative medicine
• Organoid technology
• Genome editing
• Biomedical research

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Government Funding: As an autonomous institute under the Department of Biotechnology, Government of India, inStem is primarily funded through government grants and subsidies. Additional revenue may come from research contracts, industry collaborations, and licensing agreements.
2. Technology Licensing: Revenue generated through technology transfer, patents licensing, and spin-off companies emerging from research outcomes.

Go-to-market motion1 record

Marketing channels5 records

Core offering

inStem is a government-funded autonomous research institute dedicated to fundamental and translational research in stem cell science and regenerative medicine, with focus on pluripotent stem cells, organoid-based disease modeling, gene editing, chromatin dynamics, and tissue engineering. The institute delivers value through PhD and postdoctoral training programs, shared research facilities, industry and academic research collaborations, technology licensing, and commercialization of translational outputs such as the KisanKavach anti-pesticide fabric technology. It is supported by sustained Department of Biotechnology, Government of India funding and is a core member of the Bangalore Life Science Cluster (BLiSC).

Product overview

The Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem) is a research institute under the Department of Biotechnology, Government of India, focused on stem cell science and regenerative medicine research. It is not a product company but rather an academic research institution that provides research facilities, PhD programs, and conducts scientific research. The institute houses various research facilities including Stem Cell Facility, inStem Pluripotent Stem Cell Bank, Mouse Genome Engineering Facility, Mass Spectrometry, CIFF, Insectary, and National Electron Cryo-Microscopy facility. It also hosts major institutional programs such as ESCORT (stem cell and organoid research platform), WoRtH (Women's Reproductive Health program), and CReATE (embryology research center). The institute's research areas include cardiovascular development, chemical biology approaches, barrier tissue homeostasis, neuro-development modeling, and metabolic regulation of cell fate.

Differentiator

Problem solved

Functional benefit

Products and services

• PhD Program in Stem Cell Science and Regenerative Medicine (I3C-BRIC) Doctoral research training program for graduate students in stem cell science and regenerative medicine, jointly offered under the I3C-BRIC framework with structured coursework, thesis research at inStem, and access to BLiSC campus resources.
• Research Collaboration and Contract Research Services Contract research and joint research collaborations in stem cell biology, disease modeling using organoids, gene editing (CRISPR-Cas9), chromatin dynamics, and drug discovery, delivered to pharma, biotech, and academic partners.
• KisanKavach Anti-Pesticide Fabric Technology Licensed anti-pesticide fabric technology developed by the Laboratory of Self-Assembled Biomaterials and Translational Research, designed to protect farmers from toxic effects of pesticides; commercialized via technology transfer and supported by granted patents.
• Lentiviral Gene Therapy Program for Hemophilia A Translational gene therapy program leveraging lentiviral vectors and stem cell science expertise to develop and clinically evaluate a gene therapy for Hemophilia A; represents inStem's clinical-stage translational output.
• Technology Licensing and Spin-Off Commercialization Formal mechanism by which external parties can license inStem-developed technologies and IP, including patents on anti-pesticide compositions and chitosan lipid nanoparticles for combination chemotherapy, with spin-off companies created from research outcomes.

Quantifiable outcome

• Established first human embryonic stem cell lines of Indian origin
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, major and strategic.

• Department of Biotechnology, Ministry of Science & Technology, Government of IndiacoreOthersPrimary funding agency and governing body under which inStem operates as an autonomous institute
• Bangalore Life Science Cluster (BLiSC)coreStrategic or Co-development PartnerShared campus with NCBS-TIFR, TIGS, and C-CAMP enabling interdisciplinary collaboration in biological research
• EMBOmajorStrategic or Co-development PartnerCollaboration on India-EMBO Lecture Course on organoids and training programs
• National University of SingaporestrategicStrategic or Co-development PartnerInternational research collaboration in life sciences
• Dr Reddy's LaboratoriesstrategicStrategic or Co-development PartnerIndustry collaboration for research translation and drug development
• NCBS-TIFRcoreStrategic or Co-development PartnerSister institute on BLiSC campus enabling research collaboration and shared resources

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Indian Institute of Science (IISc) Bangalore: Premier Indian research university in the same Bengaluru ecosystem. Operates a broad biotechnology division with overlapping interests in stem cells, chemical biology, and cryo-EM; competes for talent and grants in the same domestic pool.
• Gladstone Institutes: UCSF-affiliated nonprofit biomedical research organization with deep regenerative medicine and stem cell programs. Closest international analogue in mission (stem cell and disease-focused research institute) and translational orientation.
• Wellcome Sanger Institute: UK-based, Wellcome Trust-funded genomics and cellular biology research institute. Larger scale and broader mandate, but directly comparable as a mission-driven, grant-funded research organization producing open-science outputs in cell biology.
• Broad Institute of MIT and Harvard: Large-scale nonprofit genomic and biomedical research institute. Much larger in scale but structurally analogous as a mission-driven, multi-funder research organization producing shared tools and translational science.
• CCMB (Centre for Cellular and Molecular Biology): Veteran Indian Council of Scientific Research (CSIR) life sciences institute in Hyderabad. Broader in scope (covering multiple biology areas) but operates under a comparable government research institute model with translational ambitions.

Direct peers

• TIGS (The Institute for Genome Research and Society): Co-located on the BLiSC campus as a DBT-funded autonomous institute. Operates with a similar government-funded research model focused on genomics and societal applications, making it a structural peer in funding/governance terms.
• NCBS (National Centre for Biological Sciences): Sister institute on the BLiSC campus under the same DBT/TIFR ecosystem. Both are autonomous Indian government life science research institutes focused on fundamental biology with shared facilities and joint programs — directly comparable operating model and funding structure.
• Centre for Stem Cell Research (CSCR), CMC Vellore: Affiliated translational stem cell research unit embedded in a hospital (CMC Vellore), explicitly listed as a research area on inStem's site. Comparable mission of moving stem cell science into clinical applications within an Indian institutional setting.
• LV Prasad Eye Institute: Indian translational research hospital where inStem's Scientist-F Indumathi Mariappan previously worked (2008-2025) on retinal/corneal stem cell disease modeling. Direct personnel and topical overlap in ophthalmic stem cell applications.
• C-CAMP (Centre for Cellular and Molecular Platforms): BLiSC campus neighbor and DBT-linked bio-incubation platform. Shares the same funding ecosystem and research-translation mandate, though more focused on startup enablement than wet-lab discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/instem_india
• YouTubeyoutube.com/@dbt-instem
• LinkedInlinkedin.com/company/institute-for-stem-cell-biology-and-regenerative-medicine
• Facebookfacebook.com/103167733360724

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute of Stem Cell